MassDevice.com +5 | The top 5 medtech stories for May 18, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Teleflex closes $400m debt offering Teleflex said Monday it closed a $400 million debt offering round through the offering of 4.875% senior notes due in 2026. The Wayne, Penn.-based company said it expects to net approximately $393 million from the offering after deducting underwriters discounts and commissions, and intends to use the proceeds to repay borrowings from its revolving credit facility, according to an SEC filing. Read more 4. Edwards touts multi-trial heart valve data Edwards Lifesciences yesterday released results from 3 trials of its surgical heart valves designed for treating aortic valve disease, touting positive clinical results from studies of over 2,000 patients. Data from the trials was presented during late-breaking sessions at the American Association for Thoracic Surgery’s 96th annual meeting this week, the company said. Read more 3. Zimmer Biomet closes Cayenne Medical buy Zimmer Biomet said today that it closed its buyout of Cayenne Medical and its soft tissue reconstruction devices for an unspecified amount. Scottsdale, Ariz.-based ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news

Related Links:

We are currently in an era of change in management and shared decision-making for heart valve disease. Aortic valve surgery in non-elderly patients represents a very challenging patient population. Their high level of physical activity places haemodynamic demands on the valve. Their post-operative quality of life is extremely important, and must be compatible with their professional and personal lifestyle. More importantly, the younger the patient is at the point of aortic valve intervention, the longer their anticipated life expectancy will be.
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: THORACIC – Review Source Type: research
(Concordia University) Using high-tech equipment to look at the flow downstream of a bi-leaflet mechanical heart valve, researchers at Concordia have devised a technique to detect obstructions in a type of mechanical heart valve they believe will contribute to safer follow-up methods for cardiologists and their patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Multivalvular heart disease (MVD) is a highly prevalent condition causing significant morbidity and mortality. The complex haemodynamic interactions between coexisting valve lesions makes the diagnosis and treatment challenging. Current guidelines may not be adequate for managing the varying clinical scenarios of MVD and, therefore, the expertise of a multidisciplinary Heart Valve Team is of paramount importance. The indications for intervention should be based on a global assessment of the consequences of the multiple valve lesions after a careful estimation of the added surgical risk of combined procedures, the long-term...
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Review Source Type: research
AbstractPurpose of reviewThe purpose of this review was to evaluate the complexities and challenges associated with transcatheter mitral valve replacement and review the existing data.Recent findingsMany patients with mitral valve disease are not candidates for cardiac surgery and are in need of less invasive transcatheter therapies. The first transcatheter mitral valve replacement (TMVR) in a native valve was performed in 2012. However, the complexities and variability of the mitral valve anatomy and its relationship to neighboring structures have resulted in slower progress with this new therapy compared to the rapid upt...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
AbstractMucopolysaccharidoses (MPS) are inborn errors of metabolism produced by a deficiency of one of the enzymes involved in the degradation of glycosaminoglycans (GAGs). Although taken separately, each type is rare. As a group, MPS are relatively frequent, with an overall estimated incidence of around 1 in 20,000 –25,000 births. Development of therapeutic options for MPS, including hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT), has modified the natural history of many MPS types. In spite of the improvement in some tissues and organs, significant challenges remain unsol ved, in...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
CorMatrix, a company out of Roswell, Georgia, has won FDA clearance for the Cor PATCH epicardial patch. The device is indicated for use at the locations of aneurysms, in adults who have suffered a heart attack that led to the ventricular walls b...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Source Type: blogs
In this study, the unique capabilities of melt electrowriting (MEW) are exploited to create functional scaffolds with highly controlled fibrous microarchitectures mimicking the wavy nature of the collagen fibers and their load ‐dependent recruitment. Scaffolds with precisely‐defined serpentine architectures reproduce the J‐shaped strain stiffening, anisotropic and viscoelastic behavior of native heart valve leaflets, as demonstrated by quasistatic and dynamic mechanical characterization. They also support the growth of human vascular smooth muscle cells seeded both directly or encapsulated in fibrin, and promote the ...
Source: Small - Category: Nanotechnology Authors: Tags: Full Paper Source Type: research
ConclusionsIn conclusion, patient-specific modelling and simulation could help to evaluate device performance prior to the actual first-in-human clinical study and, combined with device optimization, could help to develop better devices in a shorter period.
Source: Cardiovascular Engineering and Technology - Category: Cardiology Source Type: research
BASILICA procedure shows successful results for some high-risk patients.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
Meril Life Sciences, a company based in India, has obtained the European CE mark of approval for its Myval transcatheter aortic heart valve. This marks the first such approval for an Indian company, highlighting how far the country’s medical de...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Source Type: blogs
More News: Cardiology | Cardiovascular & Thoracic Surgery | Cayenne | Gastroschisis Repair | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Hysteroscopy | Medical Devices | Men | Middle East Health | Study